Progesterone in Phase III trials

Share


don_stein_520
There continues to be a search for the drug which can address the complex neurological events which occur after brain injury. Progesterone, a female hormone, holds out promise in the search. Now in Phase III trials in to studies: Protect III and SyNAPSE, Progesterone may soon enter into use immediately following a brain injury to reduce the neurotoxic effects which occur at the cellular level and prevent the death of brain cells which continue past the original injury. Don Stein, PhD, at Emory University leads the research into Progesterone and his research work is receiving the wide recognition it deserves.

Click here to read an article about progesterone and brain injury.

About Rolf Gainer Ph.D.

Dr. Rolf Gainer is the founder of the Neurologic Rehabilitation Institute at Brookhaven Hospital in Tulsa, Oklahoma as well as the Neurological Rehabilitation Institute of Ontario, in Toronto, Canada. Dr. Gainer is a psychologist with more than twenty-five years of experience in the treatment and rehabilitation of individuals with brain injuries and a dual diagnosis. Dr. Gainer has designed and operated innovative rehabilitation programs in the United States and Canada for individuals who have been regarded as difficult to serve. He is currently involved in conducting two outcome studies related to the long-term issues faced by individuals with brain injuries and a dual diagnosis. He has presented papers throughout the United States and Canada in many professional conferences and educational forums.

, , , , ,

No comments yet.

Leave a Reply